journal
Journals Journal of Dermatological Trea...

Journal of Dermatological Treatment

https://read.qxmd.com/read/37694979/safety-and-efficacy-of-hyaluronic-acid-injectable-filler-in-the-treatment-of-nasolabial-fold-wrinkle-a-randomized-double-blind-self-controlled-clinical-trial
#1
JOURNAL ARTICLE
Xing-Zhou Li, Chi-Fu Chiang, Yung-Hsiang Lin, Tim-Mo Chen, Chih-Hsing Wang, Yuan-Sheng Tzeng, Hai-Yan Cui
INTRODUCTION: The injectable skin fillers available for soft tissue augmentation are constantly growing, providing esthetic surgeons with more options in the treatment of scars, lines, and wrinkles. Hyaluronic acid (HA)-derived injectable fillers are ideal to reduce the appearance of nasolabial folding. This study investigated the efficacy and safety of the commercially available HA filler from Maxigen Biotech Inc. (MBI-FD) in the treatment of nasolabial folds (NLFs). METHODS: We analyzed 1,4-butanediol diglycidyl ether (BDDE) residues and injection force test and observed the protein content in MBI-FD, and then was cultured in fibroblast L929 cells and examined for cytotoxicity...
September 11, 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37705378/paradoxical-tralokinumab-induced-psoriasis-in-a-patient-with-atopic-dermatitis
#2
JOURNAL ARTICLE
Galina Balakirski, Sven-Niklas Burmann, Silke C Hofmann, Alexander Kreuter
Purpose: Although psoriasis and atopic dermatitis (AD) were for decades considered to be opposing diseases, it is now known that these skin conditions can coexist or even overlap in the same individual. Especially when using modern drugs with targeted IL inhibition, the balance between Th1 and Th2 immunity can be disturbed. In line with it, numerous clinical cases of AD have been induced by antipsoriatic biologics (e.g., TNF-alpha, IL-23, or IL-17 inhibitors), and IL-4-/IL-13 inhibition by dupilumab also resulted in paradoxical psoriasis in patients with AD...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37705359/adalimumab-induced-paradoxical-pustular-psoriasis-and-alopecia-successfully-treated-with-ixekizumab-in-a-patient-affected-by-hidradenitis-suppurativa
#3
JOURNAL ARTICLE
Carlo Alberto Vignoli, Luigi Gargiulo, Federica Sanna, Alessandra Narcisi, Antonio Costanzo
No abstract text is available yet for this article.
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37700698/modalities-of-treatment-for-nevus-depigmentosus-review-of-the-literature
#4
REVIEW
Saad Altalhab
BACKGROUND: Nevus depigmentosus (ND) is one of the pigmentary conditions that is characterized by a hypopigmented patch with an irregular border. It is usually present at birth or shortly after birth. It is not a progressive condition, but it may increase in size in proportion to the growth of the body. Despite many treatment modalities, there is no effective treatment for this condition. OBJECTIVE: To review all articles about the treatment options for ND. METHODS: Pubmed database were searched for this study, and relative clinical trials were included in the review...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37700510/expert-opinion-on-management-of-moderate-to-severe-atopic-dermatitis-in-qatar
#5
REVIEW
Martin Steinhoff, Mehdi Adeli, Hassan Riad, Mohamed Allam, Ahmad Hazem, Ra'ed Alsmadi, Adel Mohamed Kamal, Waad Ibrahim, Maryam Ali Al-Nesf
Atopic dermatitis (AD), a chronic-relapsing inflammatory skin disorder, manifests with intense itching and eczematous lesions impairing quality of life. A heterogeneous population, and regional clinical practices for treating AD warrant the development of guidelines in Qatar. Therefore, guidelines for the management of moderate-to-severe AD in Qatar have been developed and discussed. Experts, including dermatologists and immunologists, used the Delphi technique for developing guidelines. Consensus was defined as ≥75% agreement or disagreement...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37691405/disease-burden-among-patients-with-atopic-dermatitis-treated-with-systemic-therapy-for-4-12-months-results-from-the-corevitas-atopic-dermatitis-registry
#6
JOURNAL ARTICLE
Jonathan I Silverberg, Evangeline Pierce, Meghan Feely, Amber Reck Atwater, Amy Schrader, Eric A Jones, Swapna S Dave, Eric L Simpson
BACKGROUND: Real-world data on the effectiveness of systemic therapy in atopic dermatitis (AD) are limited. METHODS: Adult patients with AD in the CorEvitas AD registry (2020-2021) who received systemic therapies for 4-12 months prior to enrollment were included based on disease severity: body surface area (BSA) 0%-9% and BSA ≥10%. Demographics, clinical characteristics, and outcomes were assessed using descriptive statistics. Pairwise effect sizes (ES) were used to compare BSA groups...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37674258/could-red-and-near-infrared-emitting-fabric-technology-improve-the-severity-of%C3%A2-psoriasis-polymorphous-light-eruption-and-alopecia-areata
#7
JOURNAL ARTICLE
Jessica N Pixley, Rithi J Chandy, Irma Richardson, Joseph L Jorizzo, Steven R Feldman
AIM: Low-level light therapy (LLLT) may offer an adjunctive therapeutic tool for inflammatory skin conditions. This pilot study assessed the efficacy of a red/near-infrared (NIR)-emitting fabric for psoriasis, polymorphous light eruption (PMLE), and alopecia areata (AA). METHODS: Fourteen patients (five with psoriasis, five with PMLE, and four with AA) were instructed to wear a red/NIR-emitting (Lumiton®) garment during the 12-week study. Efficacy was assessed subjectively by patient-reported improvement and objectively by the redness, thickness, and scale of elbow psoriasis plaques, the frequency of PMLE flares, and the Severity of Alopecia Tool (SALT) score...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37664977/biologicals-for-pediatric-patients-with-atopic-dermatitis-practical-challenges-and-knowledge-gaps
#8
JOURNAL ARTICLE
Lisa P van der Rijst, Annet van Royen-Kerkhof, Suzanne G M A Pasmans, Renske Schappin, Marjolein S de Bruin-Weller, Marlies de Graaf
Biologicals are becoming increasingly important in the therapeutic landscape of pediatric patients with moderate-to-severe atopic dermatitis (AD). Currently, dupilumab and tralokinumab are registered for the treatment of moderate-to-severe AD, and novel biologicals are expected to follow. Dupilumab was the first biological registered for AD in pediatric patients and was recently approved for patients aged six months to five years. Current and emerging biologicals may address the unmet need for effective and safe treatment options for pediatric AD patients, however, little is known about the practical implementation of biologicals in infants and preschoolers (aged <6 years), including the timing of treatment initiation, discontinuation, and long-term administration of the subcutaneous injections...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37661936/upadacitinib-in-nail-psoriasis-a-case-report
#9
REVIEW
Na Wang, Qing Yang, Yongxia Liu, Hong Liu
THE PURPOSE OF THE ARTICLE: Nail psoriasis is a refractory disease that affects 50-79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA). The pathogenesis of nail psoriasis is still not fully illuminated, although some peculiar inflammatory cytokines and chemokines seems to be the same as described in psoriatic skin lesions. Treatment of nail psoriasis still with challenge and should be individualized. Upadacitinib, an oral highly selective JAK1 inhibitor, has been approved for PsA treatment...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37644869/comparison-of-the-efficacy-of-tacrolimus-0-1-ointment-vs-calcipotriol-betamethasone-in-combination-with-nbuvb-in-treatment-of-vitiligo
#10
COMPARATIVE STUDY
Diala Alshiyab, Firas Al-Qarqaz, Saleh Ba-Shammakh, Abdulqudos Al-Fakih, Aya Altawalbeh, Safa' Alsheyab, Danyah Sarakbi, Jihan Muhaidat
Purpose: Vitiligo is an idiopathic depigmenting skin disorder. The study compares the efficacy of topical tacrolimus 0.1% with calcipotriol/betamethasone dipropionate in vitiligo patients receiving NB-UVB treatment. Materials and methods: Forty-one adult patients with generalized type vitiligo were recruited. Patients were assigned to phototherapy and then classified into either group one (20 patients), receiving calcipotriol/betamethasone dipropionate cream (D group), or group two (21 patients), receiving tacrolimus 0...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37621166/the-economic-burden-and-quality-of-life-of-patients-with-psoriasis-treated-with-biologics-in-china
#11
JOURNAL ARTICLE
Shuhui Min, Danfeng Wang, Jiali Xia, Xiao Lin, Guan Jiang
BACKGROUND: Although biologics improve the quality of life of psoriasis patients, they also impose a substantial economic burden. There is a lack of research addressing the economic and humanistic impact of biologics in China. OBJECTIVE: This cross-sectional investigation aims to assess the economic cost, quality of life, and patient satisfaction among individuals with psoriasis treated with biologics and non-biologics. METHODS: From July 2021 to December 2022, eligible patients with psoriasis were recruited through both on-site and online questionnaire completion...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37621164/potential-biomarkers-for-psoriasis-topical-treatment-by-in-depth-serum-proteomics
#12
JOURNAL ARTICLE
Jingwen Cui, Xiaomei Zhang, Jingwen Deng, Yuhong Yan, Danni Yao, Hao Deng, Jingjie Yu, Shuyan Ye, Ling Han, Xiaobo Yu, Chuanjian Lu
BACKGROUND: Psoriasis is a chronic skin disease, and topical sequential therapy with a combination of calcipotriol and calcipotriol betamethasone is currently approved topical treatment. However, the exact mechanism by which this treatment regimen relieves psoriasis is unknown. METHOD: We assembled a cohort of 65 psoriasis patients and divided post-treatment cohort into responder group and non-responder group according to the Psoriasis Area Severity Index (PASI) score after 12-week treatment...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37608703/efficacy-and-safety-evaluations-of-adalimumab-biosimilars-in-the-treatment-of-psoriasis
#13
REVIEW
Changkun Li, Yixuan Sunhe, Hui Zhou, Weihua Dong
PURPOSE: We aimed to systematically evaluate the efficacy and safety of adalimumab biosimilar agents in the treatment of moderate-to-severe plaque psoriasis, in order to provide evidence-based reference data for clinical medicine. MATERIALS AND METHODS: Five databases were searched by electronic retrieval: PubMed, Embase, Cochrane Library, WanFang and CNKI (China National Knowledge Internet). The retrieval period was from the establishment of each database up to April 2022...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37605482/two-cases-of-lupus-miliaris-disseminatus-faciei-successfully-treated-with-oral-tofacitinib
#14
JOURNAL ARTICLE
Xinyi Chen, Jianjun Qiao
No abstract text is available yet for this article.
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37599384/efficacy-and-safety-of-topical-acetylcysteine-combined-with-the-use-of-an-overcurvature-correcting-device-in-patients-with-pincer-nail-deformity-a-randomized-vehicle-controlled-investigator-blinded-study
#15
JOURNAL ARTICLE
Masataka Saito, Akihiko Ikoma, Akira Fujikawa, Kazuaki Tanaka
BACKGROUND: While pincer nails may be treated using overcurvature-correcting devices, it takes several months to achieve successful outcomes. Nail-softening drugs may reduce the treatment duration required. OBJECTIVE: To evaluate the efficacy and safety of treatment with acetylcysteine (AC) gel added to an overcurvature-correcting device, and define the optimal AC concentration. METHODS: In this investigator-blinded study, 70 patients with hallux pincer nail were fitted with an overcurvature-correcting device for 7 days and were randomly assigned to receive a single 24-h administration of a gel containing 10%, 20% or 30% AC or vehicle...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37592879/a-1-colloidal-oatmeal-otc-cream-is-clinically-effective-for-the-management-of-mild-to-moderate-atopic-dermatitis-in-black-or-african-american-children
#16
JOURNAL ARTICLE
Toni Anne Lisante, Menas Kizoulis, Christopher Nuñez, Corey L Hartman
BACKGROUND: The efficacy and safety of an over-the-counter (OTC) 1% colloidal oatmeal cream versus a ceramide-based prescription barrier cream in children with mild-to-moderate atopic dermatitis (AD) were previously described. OBJECTIVES: Here, findings are reported for the Black/African American subgroup. METHODS: Patients were randomized to 1% oatmeal cream or prescription barrier cream twice daily or as needed for three weeks. Assessments included Eczema Area and Severity Index (EASI) scores, Investigator's Global Atopic Dermatitis Assessment (IGADA) scores, and patients'/caregivers' assessment of eczema signs and symptoms...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37587870/ixekizumab-is-effective-in-the-long-term-management-in-moderate-to-severe-plaque-psoriasis-results-from-an-italian-retrospective-cohort-study-the-lotixe-study
#17
JOURNAL ARTICLE
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang, Alessandra Narcisi
PURPOSE: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to describe the real-world long-term effectiveness of ixekizumab in patients with plaque psoriasis in Italy. MATERIALS AND METHODS: A retrospective study was conducted in patients affected by moderate-to-severe plaque psoriasis who were continuously treated with ixekizumab for at least 12 months...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37587862/patients-willingness-to-accept-adverse-event-and-cost-tradeoffs-from-oral-nicotinamide-for-reduced-risk-of-non-melanoma-skin-cancer
#18
RANDOMIZED CONTROLLED TRIAL
Marco Boeri, Maral K Skelsey, James A Schiro, Susan E Dozier, Robert Glinert, Martin M Okun
BACKGROUND: Non-immunosuppressed patients with a history of multiple non-melanoma skin cancers (NMSCs) taking oral nicotinamide supplementation experienced a 23% decrease in annual NMSC risk in a randomized clinical trial. Patient preferences for risks and costs associated with nicotinamide are unknown. OBJECTIVES: To understand how patients prioritize NMSC reduction, infection risk, and cost. METHODS: A sample of adults with history of ≥2 NMSC within the past five years undergoing Mohs procedure completed a discrete-choice experiment comprising two hypothetical treatments-characterized by varying reductions in NMSC incidence, increased severe infection risk, and cost-and no treatment...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37580895/a-52-week-multicenter-retrospective-real-world-study-on-effectiveness-and-safety-of-dupilumab-in-children-with-atopic-dermatitis-aged-from-6-to-11-years
#19
MULTICENTER STUDY
Cataldo Patruno, Gabriella Fabbrocini, Giuseppe Lauletta, Valeria Boccaletti, Cristiana Colonna, Riccardo Cavalli, Iria Neri, Michela Ortoncelli, Donatella Schena, Luca Stingeni, Katharina Hansel, Vincenzo Piccolo, Veronica Di Brizzi, Concetta Potenza, Ersilia Tolino, Luca Bianchi, Sara Manti, Rocco De Pasquale, Vito Di Lernia, Lucia Caminiti, Elena Galli, Paola Coppo, Andrea Chiricozzi, Clara De Simone, Cristina Guerriero, Fabrizio Giuseppe Amoruso, Eugenio Provenzano, Salvatore Leonardi, Amelia Licari, Gian Luigi Marseglia, Antonino Palermo, Sabrina Di Pillo, Daniele Russo, Viviana Moschese, Vincenzo Patella, Tiziana Peduto, Caterina Ferreli, Paola Zangari, Federica Veronese, Samantha Federica Berti, Michaela Gruber, Elena Pezzolo, Stefania Termine, Rosanna Satta, Federica Dragoni, Maria Esposito, Maria Concetta Fargnoli, Paolo Chiodini, Ylenia Vallone, Francesca di Vico, Vincenzo Picone, Maddalena Napolitano
Background: Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determine the effectiveness in disease control and safety of dupilumab at W52 in moderate-to-severe AD children aged 6-11 years. Methods: All data were collected from 36 Italian dermatological or paediatric referral centres. Dupilumab was administered at label dosage with an induction dose of 300 mg on day 1 (D1), followed by 300 mg on D15 and 300 mg every 4 weeks (Q4W)...
December 2023: Journal of Dermatological Treatment
https://read.qxmd.com/read/37577796/a-hyaluronic-acid-based-micro-filler-improves-superficial-wrinkles-and-skin-quality-a-randomized-prospective-controlled-multicenter-study
#20
JOURNAL ARTICLE
Ferial Fanian, Jean-Jacques Deutsch, Marie Thérèse Bousquet, Sylvie Boisnic, Pierre Andre, Isabelle Catoni, Ghislaine Beilin, Christian Lemmel, Maryna Taieb, Marie Gomel-Toledano, Hanane Issa, Philippe Garcia
BACKGROUND: NCTF®135HA is a bio-revitalizing solution containing hyaluronic acid designed to compensate for skin dehydration, fatigue, and fine wrinkles associated with endogenous and environmental aging. METHODS: We conducted a randomized, active-controlled study to evaluate the efficacy and tolerability of NCTF®135HA injections on the face (crow's feet), neck, and décolleté regions. Subjects were randomly assigned (3:1) to receive three NCTF®135HA treatment sessions plus twice-daily anti-aging moisturizer cream or cream alone (control)...
December 2023: Journal of Dermatological Treatment
journal
journal
30315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.